サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363099

鉄欠乏性貧血治療の市場規模、シェア、動向分析レポート：治療タイプ別、年齢層別、エンドユーザー別、地域別、セグメント別予測、2023年～2030年

Iron Deficiency Anemia Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy), By Age Group, By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
鉄欠乏性貧血治療の市場規模、シェア、動向分析レポート：治療タイプ別、年齢層別、エンドユーザー別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月20日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

鉄欠乏性貧血治療市場の成長と動向：

Grand View Research社の最新調査によると、世界の鉄欠乏性貧血治療市場規模は2030年までに80億6,000万米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 7.6%で成長すると予測されています。月経時の異常多量出血や分娩後出血の症例が増加していることが、若い女性におけるIDA療法の採用率を高めている主な要因です。さらに、女性の栄養健康に対する意識の高まり、非経口栄養サプリメントの進歩、新規製品の発売などが、鉄欠乏性貧血（IDA）療法市場の成長を促進する主な要因となっています。

2023年3月に更新された国立医学図書館の報告書によると、月経困難症の年間有病率は女性1,000人当たり53人です。2018年6月に国立医学図書館が発表した別の論文によると、更年期年齢層におけるIDA症例の約5～10％は、月経困難症（月経血量が多い）などの月経障害が寄与しているといいます。さらに、栄養鉄欠乏症が更年期女性の間ですでに蔓延している発展途上諸国では、月経困難症が悪化因子となり、重度の貧血につながります。

人々の意識の高まり、女性の栄養健康に対する地域政府による戦略的イニシアティブ、非経口栄養サプリメントの進歩、新規製品の発売などは、世界のIDA療法市場成長の主な促進要因のひとつです。例えば、インドでは2023年2月にケララ州政府が中央政府のAnaemia Mukt Bharatプログラムに加え、イニシアチブを開始しました。このキャンペーンは、6ヵ月以内に州全体で約1,300万人の女性にリーチすることを目標としていました。貧血の負担を軽減するための段階的な介入策をテストし実施するために、戸別訪問キャンペーンが実施されました。

業界大手は、製品ポートフォリオを強化するため、提携や買収に取り組んでいます。例えば、2022年11月、CSL ViforとFresenius Kabiは、静注鉄剤Ferinjectが成人患者の鉄欠乏症治療薬として中国のNMPAから承認を取得したと発表しました。フェリンジェクトは、経口製剤が無効または不適当な場合、あるいは臨床的に迅速な鉄投与が必要な場合に適応されます。当時、両社は2023年前半にフェリンジェクトの販売を開始する予定であり、この承認により85カ国で販売認可を取得し、2024年1月にNRDLへの上場を予定していました。これは、市場でのプレゼンスを高め、世界的にフェリンジェクトへの患者アクセスを拡大する機会を意味します。同様に、サンドは2021年7月、米国で鉄欠乏性貧血治療薬として初の高用量鉄剤静注ジェネリックである、費用対効果の高いフェルモキシトール注射剤を発売しました。

鉄欠乏性貧血治療市場レポート・ハイライト

  • 鉄欠乏性貧血治療市場全体の成長は、世界中で鉄欠乏に伴う貧血の有病率が増加していることに起因しています。
  • 特に慢性または重症度の低い鉄欠乏性貧血患者にとっては魅力的です。
  • 非経口鉄剤療法は、2022年に治療法の種類別で最大のシェアを占めました。これは、非経口鉄剤の進歩や、同市場で事業を展開する主要企業による新製品の発売によるものです。
  • 成人年齢層セグメントは2022年に63.87%の最大売上シェアを占めました。これは、多忙なライフスタイルと不適切な食生活が、成人の鉄欠乏性貧血の広範な有病率に寄与しているためです。
  • 北米は、複数の主要企業の存在と、同地域における鉄欠乏性貧血の負担を克服するための政府からの支援の高まりにより、2022年の市場を独占しました。
  • 同市場の主要企業は、新製品発売、パートナーシップ、提携などの戦略を採用し、世界の地域拡大を図っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 治療タイプ型ビジネス分析

  • 鉄欠乏性貧血治療市場：治療タイプの変動分析
  • 経口鉄療法
  • 非経口鉄療法
  • 赤血球輸血
  • その他

第5章 年齢層別ビジネス分析

  • 鉄欠乏性貧血治療市場：年齢層の変動分析
  • 大人
  • 小児
  • 高齢者

第6章 エンドユーザー別ビジネス分析

  • 鉄欠乏性貧血治療市場：エンドユーザーの変動分析
  • クリニック
  • 病院
  • 在宅ヘルスケア

第7章 地域別ビジネス分析

  • 地域別鉄欠乏性貧血治療市場シェア、2022年および2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 参入企業
  • 戦略マッピング
    • 新製品の発売
    • パートナーシップ
    • コラボレーション
  • 主要企業の市場シェア分析、2022年
  • 企業プロファイル
    • Akebia Therapeutics, Inc.
    • Bayer AG
    • PHARMACOSMOS A/S
    • Sanofi
    • Johnson &Johnson Services, Inc.
    • CSL Vifor
    • AbbVie Inc.（Allergan）
    • Novartis AG
    • Teoxane
    • Zydus Group
    • GSK plc
    • AdvaCare Pharma
    • Apotex Inc.
    • Covis Pharma GmbH
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Iron Deficiency Anemia Therapy Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 4 Global Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 5 Global Iron Deficiency Anemia Therapy Market, By End-User, 2018 - 2030 (USD Million)
  • Table 6 Global Iron Deficiency Anemia Therapy Market, By Region, 2018 - 2030 (USD Million)
  • Table 7 North America Iron Deficiency Anemia Therapy Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Iron Deficiency Anemia Therapy Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 9 North America Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 10 North America Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 11 US Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 12 US Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 13 US Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 14 Canada Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 16 Canada Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 17 Europe Iron Deficiency Anemia Therapy market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 19 Europe Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 21 UK Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 22 UK Iron Deficiency Anemia Therapy Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 23 UK Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 24 Germany Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 26 Germany Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 27 France Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 28 France Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 29 France Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 30 Italy Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 32 Italy Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 33 Spain Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 35 Spain Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 36 Denmark Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 37 Denmark Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 38 Denmark Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 39 Sweden Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 40 Sweden Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 41 Sweden Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 42 Norway Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 43 Norway Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 44 Norway Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Iron Deficiency Anemia Therapy market, by country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 49 Japan Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 51 Japan Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 52 China Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 53 China Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 54 China Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 55 India Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 56 India Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 57 India Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 58 Australia Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 59 Australia Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 60 Australia Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 61 Thailand Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 62 Thailand Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 63 Thailand Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 64 South Korea Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 66 South Korea Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 67 Latin America Iron Deficiency Anemia Therapy market, by country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 69 Latin America Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 70 Latin America Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 71 Brazil Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 73 Brazil Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 74 Mexico Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 75 Mexico Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 76 Mexico Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 77 Argentina Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 79 Argentina Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Iron Deficiency Anemia Therapy market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 84 South Africa Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 86 South Africa Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 90 UAE Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 92 UAE Iron Deficiency Anemia Therapy market, by End-User, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Iron Deficiency Anemia Therapy market, by Therapy Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Iron Deficiency Anemia Therapy market, by Age Group, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Iron Deficiency Anemia Therapy market, by End-User, 2018-2030, (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Iron deficiency anemia therapy, market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Market challenge relevance analysis (current & future impact)
  • Fig. 13 SWOT analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Global iron deficiency anemia therapy market: Therapy Type movement & market share analysis
  • Fig. 16 Global iron deficiency anemia therapy market, for oral iron therapy, 2018 - 2030 (USD Million)
  • Fig. 17 Global iron deficiency anemia therapy market, for parenteral iron therapy, 2018 - 2030 (USD Million)
  • Fig. 18 Global iron deficiency anemia therapy market, for red blood cell transfusion, 2018 - 2030 (USD Million)
  • Fig. 19 Global iron deficiency anemia therapy market, for other therapies, 2018 - 2030 (USD Million)
  • Fig. 20 Global iron deficiency anemia therapy market: Age group movement & market share analysis
  • Fig. 21 Global iron deficiency anemia therapy market, for adults, 2018 - 2030 (USD Million)
  • Fig. 22 Global iron deficiency anemia therapy market, for pediatric, 2018 - 2030 (USD Million)
  • Fig. 23 Global iron deficiency anemia therapy market, for geriatric, 2018 - 2030 (USD Million)
  • Fig. 24 Global iron deficiency anemia therapy market: End-user movement & market share analysis
  • Fig. 25 Global iron deficiency anemia therapy market, for clinics, 2018 - 2030 (USD Million)
  • Fig. 26 Global iron deficiency anemia therapy market, for hospitals, 2018 - 2030 (USD Million)
  • Fig. 27 Global iron deficiency anemia therapy market, for home healthcare, 2018 - 2030 (USD Million)
  • Fig. 28 Regional marketplace: key takeaways
  • Fig. 29 Regional outlook, 2022 & 2030
  • Fig. 30 Global iron deficiency anemia therapy market: region movement analysis
  • Fig. 31 North America iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 32 US key country dynamics
  • Fig. 33 US iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada key country dynamics
  • Fig. 35 Canada iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 37 UK key country dynamics
  • Fig. 38 UK iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany key country dynamics
  • Fig. 40 Germany iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 41 France key country dynamics
  • Fig. 42 France iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 43 Italy key country dynamics
  • Fig. 44 Italy iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain key country dynamics
  • Fig. 46 Spain iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark key country dynamics
  • Fig. 48 Denmark iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden key country dynamics
  • Fig. 50 Sweden iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway key country dynamics
  • Fig. 52 Norway iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan key country dynamics
  • Fig. 55 Japan iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 56 China key country dynamics
  • Fig. 57 China iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 58 India key country dynamics
  • Fig. 59 India iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 60 Australia key country dynamics
  • Fig. 61 Australia iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand key country dynamics
  • Fig. 63 Thailand iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea key country dynamics
  • Fig. 65 South Korea iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil key country dynamics
  • Fig. 68 Brazil iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico key country dynamics
  • Fig. 70 Mexico iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina key country dynamics
  • Fig. 72 Argentina iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East and Africa iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa key country dynamics
  • Fig. 75 South Africa iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia key country dynamics
  • Fig. 77 Saudi Arabia iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE key country dynamics
  • Fig. 79 UAE iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait key country dynamics
  • Fig. 81 Kuwait iron deficiency anemia therapy market, 2018 - 2030 (USD Million)
  • Fig. 82 Company market position analysis
  • Fig. 83 Company/competition categorization
  • Fig. 84 Strategy mapping
目次
Product Code: GVR-4-68040-124-0

Iron Deficiency Anemia Therapy Market Growth & Trends:

The global iron deficiency anemia therapy market size is expected to reach USD 8.06 billion by 2030, as per a new study by Grand View Research, Inc.. The market is projected to grow at a CAGR of 7.6% from 2023 to 2030. Rising cases of abnormally heavy bleeding during menstruation and post-partum hemorrhage are some major factors increasing the adoption rate of IDA therapy in young women. Moreover, rising awareness for women's nutritional health, advancing parenteral nutrition supplements, and novel product launches are some key drivers fueling the market growth for iron deficiency anemia (IDA) therapy.

According to a National Library of Medicine report updated in March 2023, the annual prevalence of menorrhagia is 53 per 1,000 women. Another article published by the National Library of Medicine in June 2018 states that menstrual disorders such as menorrhagia (heavy menstrual blood loss) contribute to approximately 5-10% of cases of IDA in the perimenopausal age group. Moreover, in developing countries where nutritional iron deficiency is already prevalent among perimenopausal women, menorrhagia is an exacerbating factor, leading to severe anemia.

Rising awareness among people and strategic initiatives by regional governments for women's nutritional health, advancing parenteral nutrition supplements, and novel product launches are some of the key driving factors for the global IDA therapy market growth. For instance, in February 2023, in India, the Kerala state government launched its initiative in addition to the Centre's Anaemia Mukt Bharat program. The campaign aimed to reach around 13 million women across the state within six months. A door-to-door campaign was conducted to test and implement graded interventions to reduce the burden of anemia.

Industry leaders are involved in collaborations & acquisitions to enhance their product portfolios. For instance, in November 2022, CSL Vifor and Fresenius Kabi announced that Ferinject, an intravenous iron therapy, had received approval from China's NMPA for treating iron deficiency in adult patients. Ferinject is indicated for cases where oral preparations are ineffective or unsuitable or when rapid iron delivery is clinically necessary. At the time, the companies planned to commence marketing Ferinject in the first half of 2023, with the approval marking its marketing authorization in 85 countries, along with an anticipated NRDL listing in January 2024. This represents an opportunity for enhanced market presence and expanded patient access to Ferinject globally. Similarly, in July 2021, Sandoz launched a cost-effective Ferumoxytol injection, the first generic intravenous high-dosage iron for treating IDA in the U.S.

Iron Deficiency Anemia Therapy Market Report Highlights:

  • The growth of the overall IDA therapy market is attributed to the increasing prevalence of anemia associated with iron deficiency across the globe
  • The market is witnessing a key shift with the rise in preference for home healthcare settings, which is especially appealing to those with chronic or less severe cases of iron deficiency anemia
  • Parenteral iron therapy held the largest share in terms of therapy type in 2022. This is owing to the advancements in parenteral iron formulations and new product launches by key companies operating in the market
  • The adult age group segment held the largest revenue share of 63.87% in 2022. This is attributed to busy lifestyles and improper diets contributing to the extensive prevalence of iron deficiency anemia in adults
  • North America dominated the market in 2022, owing to the presence of several key players and rising support from governments for overcoming the burden of IDA in the region
  • Key players in the market are adopting strategies such as new product launches, partnerships, and collaborations, among others to expand their global geographical reach

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation And Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Therapy Type Segment
      • 1.1.1.2. Age Group Segment
      • 1.1.1.3. End-User Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Or Data Analysis
  • 1.7. Market Model
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Therapy Type and Age Group Snapshot
  • 2.3. End-user Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing global elderly population
      • 3.2.1.2. Increasing prevalence of iron deficiency anemia
      • 3.2.1.3. Growing government initiatives to overcome the burden of iron deficiency
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Side effects associated with certain IDA therapies
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

  • 4.1. Iron Deficiency Anemia Therapy Market: Therapy Type Movement Analysis
  • 4.2. Oral Iron Therapy
    • 4.2.1. Oral Iron Therapy Market, 2018 - 2030 (USD Million)
  • 4.3. Parenteral Iron Therapy
    • 4.3.1. Parenteral Iron Therapy Market, 2018 - 2030 (USD Million)
  • 4.4. Red Blood Cell Transfusion
    • 4.4.1. Red Blood Cell Transfusion Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Age Group Business Analysis

  • 5.1. Iron Deficiency Anemia Therapy Market: Age Group Movement Analysis
  • 5.2. Adults
    • 5.2.1. Adults Market, 2018 - 2030 (USD Million)
  • 5.3. Pediatric
    • 5.3.1. Pediatric Market, 2018 - 2030 (USD Million)
  • 5.4. Geriatric
    • 5.4.1. Geriatric Market, 2018 - 2030 (USD Million)

Chapter 6. End-User Business Analysis

  • 6.1. Iron Deficiency Anemia Therapy Market: End-User Movement Analysis
  • 6.2. Clinics
    • 6.2.1. Clinics Market, 2018 - 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4. Home Healthcare
    • 6.4.1. Home Healthcare Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Iron Deficiency Anemia Therapy Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. SWOT Analysis
    • 7.2.2. North America Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.2.3. U.S.
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. U.S. Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.2.4. Canada
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Canada Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. UK Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Germany Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. France Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Italy Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Spain Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Denmark Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Sweden Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Norway Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Japan Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. China Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. India Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Australia Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Thailand Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. South Korea Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Brazil Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Mexico Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Argentina Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. South Africa Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Saudi Arabia Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. UAE Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Kuwait Iron Deficiency Anemia Therapy Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partnerships
    • 8.2.3. Collaboration
  • 8.3. Key Company Market Share Analysis, 2022
  • 8.4. Company Profiles
    • 8.4.1. Akebia Therapeutics, Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Bayer AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. PHARMACOSMOS A/S
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Sanofi
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services, Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. CSL Vifor
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. AbbVie Inc. (Allergan)
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Novartis AG
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Teoxane
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Zydus Group
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives
    • 8.4.11. GSK plc
      • 8.4.11.1. Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. AdvaCare Pharma
      • 8.4.12.1. Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Strategic Initiatives
    • 8.4.13. Apotex Inc.
      • 8.4.13.1. Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Strategic Initiatives
    • 8.4.14. Covis Pharma GmbH
      • 8.4.14.1. Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Strategic Initiatives